Higher‐risk myelodysplastic syndrome in an elderly patient: Long‐term partial remission with low‐dose prednisone, G‐CSF, and epoetin alfa

Abstract

Abstract Currently, most patients with higher‐risk MDS are treated with 5‐azacitidine or decitabine. These agents are toxic. The treatment described here is safe, devoid of toxicity, fosters improved quality of life, and helps reduce transfusion requirements.

Keywords

• erythropoietin (EPO)
• G‐CSF
• higher‐risk
• myelodysplastic syndrome
• prednisone